Ryotaro Nakamura, M.D.
1991, Kumamoto University School of Medicine, M.D.
1998-2001, Fellow, Hematology/Oncology, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland
1995-1998, Resident, Thomas Jefferson University Hospital, Philadelphia, PA
1993-1994, Resident and Chief Resident (1994) in Internal Medicine, Iizuka Hospital, Fukuoka, Japan
1991-1993, Resident, Kumamoto University Hospital, Kumamoto, Japan
2019-present, Professor, Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope
2009-2019, Associate Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope
2011-present, Member, City of Hope's Hematologic Malignancies Program
2008-present, Associate Chair, Cancer Protocol Review and Monitoring Committee, City of Hope
2002-present, Staff Physician, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
2012-present, Steering Committee member, BMT-Clinical Trial network
2004-2009, Assistant Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope
The 2021 Transplantation & Cellular Therapy Meeting, Best Abstract Award: A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome Blood and Marrow Transplant Clinical Trials Network Study 1102
Hope Colleague Award 2021 (City of Hope)2008-2009, Recipient, Tim Nesvig Lymphoma Fellowship Award
2000, Fellows Travel Award for the 10th Annual Mayo Clinic Jacksonville Hematology/Oncology Reviews. Intensive immunosuppression with high-dose cyclophosphamide and autologous CD34+ selected hematopoietic cell support for treatment of chronic refractory autoimmune thrombocytopenia: Jacksonville, Florida
2019-present, Co-Chair, CIBMTR Chronic Leukemia Working Committee
2019-present, Member, NCI Lymphoma Steering Committee (BMT CTN representative)
2019-present, Member, NCCN HCT Committee
2020-present, NIH-Special Emphasis Panel (SEP) reviewer, ZRG1 IMM-H(02)M
2019-present, Member, NCCN HCT Committee
American Medical Association
American Society of Hematology
American College of Physicians
Japanese Society of Internal Medicine
American Society for Blood and Marrow Transplantation
Hillmen P, Young NS, Schubert J, Brodsky RA, Socié G, Muus P, Röth A, Szer J, Elebute MO, Nakamura R, Browne P, Risitano AM, Hill A, Schrezenmeier H, Fu CL, Maciejewski J, Rollins SA, Mojcik CF, Rother RP, Luzzatto L. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006 Sep 21;355(12):1233-43.PMID: 16990386
Nakamura R, Auayporn N, Smith DD, Palmer J, Sun JY, Schriber J, Pullarkat V, Parker P, Rodriguez R, Stein A, Rosenthal J, Wang S, Karanas C, Gaal K, Senitzer D, Forman SJ. Impact of graft cell dose on transplant outcomes following unrelated donor allogeneic peripheral blood stem cell transplantation: higher CD34+ cell doses are associated with decreased relapse rates. Biol Blood Marrow Transplant. 2008 Apr;14(4):449-57.PMID: 18342788
*Rodriguez R, *Nakamura R (co-first author), Palmer JM, Parker P, Shayani S, Nademanee A, Snyder D, Pullarkat V, Kogut N, Rosenthal J, Smith E, Karanes C, O'Donnell M, Krishnan AY, Senitzer D, Forman SJ. Tacrolimus and Sirolimus as GVHD Prophylaxis for HLA-MRD Allogeneic HCT Conditioned with 3 Regimens. Blood. 2010 Feb 4;115(5):1098-105. Epub 2009 Nov 19. Erratum in: Blood. 2010 May 27;115(21):4318. PMID: 19965688
Nakamura R, La Rosa C, Tsai W, Lacey S, Srivastava T, Seidel A, Senitzer D, Forman SJ, Diamond DJ. Ex vivo detection of CD8 T cells specific for H-Y minor histocompatibility antigens in allogeneic hematopoietic stem cell transplant recipients. Transpl Immunol. 2014 May;30(4):128-35. PMID: 24582729
Nakamura R, La Rosa C, Longmate J, Drake J, Slape C, Zhou Q, Lampa MG, O’Donnell M, Cai J, Farol L, Salhotra A, Snyder DS, Aldoss I, Forman SJ, Miller JS, Zaia JA, Diamond DJ. Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial. Lancet Haematol. 2016 Feb;3(2):e87-98.
Aldoss I, Pham A, Li SM, Gendzekhadze K, Afkhami M, Telatar M, Hong H, Padeganeh A, Bedell V, Cao T, Khaled SK, Al Malki MM, Salhotra A, Ali H, Aribi A, Palmer J, Aoun P, Spielberger R, Stein AS, Snyder D, O'Donnell MR, Murata-Collins J, Senitzer D, Weisenburger D, Forman SJ, Pullarkat V, Marcucci G, Pillai R, Nakamura R. Favorable impact of allogeneic stem cell transplantation in patients with therapy-related myelodysplasia regardless of TP53 mutational status. Haematologica. 2017 Sep 29. pii: haematol.2017.172544. doi: 10.3324/haematol. 2017.172544. PMID: 28971906
Armenian SH, Xiao M, Berano Teh J, Lee B, Chang HA, Mascarenhas K, Lee S, Iukuridze A, Xie JJ, Scott JM, Jones LW, Wong FL, Forman SJ, Nakamura R. Impact of sarcopenia on adverse outcomes after allogeneic hematopoietic cell transplantation. J Natl Cancer Inst. 2019;111(8): djy231.
Aldoss I, La Rosa C, Baden LR, Longmate J, Ariza-Heredia EJ, Rida WN, Lingaraju CR, Zhou Q, Martinez J, Kaltcheva T, Dagis A, Hardwick N, Issa NC, Farol L, Nademanee A, Al Malki MM, Forman S, *Nakamura R (Co-Senior Author), *Diamond DJ; TRIPLEX VACCINE Study Group. Poxvirus Vectored Cytomegalovirus Vaccine to Prevent Cytomegalovirus Viremia in Transplant Recipients: A Phase 2, Randomized Clinical Trial. Ann Intern Med. 2020 Feb 11. doi: 10.7326/M19-2511. PMID: 32040960
Nakamura R, Saber W, Martens MJ, Ramirez A, Scott B, Oran B, Leifer E, Tamari R, Mishra A, Maziarz RT, McGuirk J, Westervelt P, Vasu S, Patnaik, Kamble R, Forman SJ, Sekeres MA, Appelbaum F, Mendizabal A, Logan B, Horowitz M, Cutler C, on behalf of the Blood and Marrow Transplant Clinical Trials Network. A Biologic Assignment Trial of Reduced Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome. J Clin Oncol. In press